Yuki Kageyama to Biomarkers
This is a "connection" page, showing publications Yuki Kageyama has written about Biomarkers.
Connection Strength
0.895
-
The relationship between circulating mitochondrial DNA and inflammatory cytokines in patients with major depression. J Affect Disord. 2018 06; 233:15-20.
Score: 0.299
-
Search for plasma biomarkers in drug-free patients with bipolar disorder and schizophrenia using metabolome analysis. Psychiatry Clin Neurosci. 2017 Feb; 71(2):115-123.
Score: 0.288
-
Nervonic acid level in cerebrospinal fluid is a candidate biomarker for depressive and manic symptoms: A pilot study. Brain Behav. 2021 04; 11(4):e02075.
Score: 0.097
-
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol Immunother. 2021 Mar; 70(3):657-665.
Score: 0.094
-
Plasma Nervonic Acid Is a Potential Biomarker for Major Depressive Disorder: A Pilot Study. Int J Neuropsychopharmacol. 2018 03 01; 21(3):207-215.
Score: 0.079
-
Levels of rheumatoid factor isotypes, metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in synovial fluid from various arthritides. Clin Rheumatol. 2000; 19(1):14-20.
Score: 0.022
-
HSP60 may predict good pathological response to neoadjuvant chemoradiotherapy in bladder cancer. Jpn J Clin Oncol. 2007 Jan; 37(1):56-61.
Score: 0.009
-
The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006 Jun; 45(6):761-4.
Score: 0.008